Evidence map›Paper›PMID 41182478›Full record

ArticleClinical pharmacokinetics2026

Low Target Attainment of Intravenous Cefuroxime in Critically Ill Term Neonates and Children: A Pooled Population Pharmacokinetics Study.

Stef Schouwenburg, Tim Preijers, Roelie M Wösten-van Asperen, Stan J F Hartman, Saskia N de Wildt, Matthijs de Hoog, Birgit C P Koch, Alan Abdulla, Enno D Wildschut

Abstract read
In one paragraph

Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stef SchouwenburgDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands. s.schouwenburg@erasmusmc.nl.ORCID 0000-0003-1835-0749
Tim PreijersDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0001-6953-0358
Roelie M Wösten-van AsperenDepartment of Pediatric Intensive Care, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.ORCID 0000-0002-2469-2131
Stan J F HartmanDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-3281-3244
Saskia N de WildtDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-0502-0647
Matthijs de HoogDepartment of Neonatal and Pediatric Intensive Care, Division of Pediatric Intensive Care, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.ORCID 0000-0002-1259-581X
Birgit C P KochDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0002-1202-3643
Alan AbdullaDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0002-2158-6376
Enno D WildschutDepartment of Neonatal and Pediatric Intensive Care, Division of Pediatric Intensive Care, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.ORCID 0009-0005-5197-2656

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveCefuroxime is a widely prescribed beta-lactam antibiotic, particularly in pediatric cardiac and medical-surgical intensive care units. The aim of this study was to describe intravenous cefuroxime disposition in critically ill pediatric patients. Moreover, target attainment of currently applied dosing regimens was evaluated, and suggestions for improving these dosing regimens were provided.

methodsTwo datasets were pooled for population pharmacokinetic (popPK) analysis, using NONMEM version 7.5. To assess the optimal target attainment (> 90% of patients with 100% time [T] > [4×] minimal inhibitory concentration [MIC]

resultsThe cohort consisted of 45 pediatric patients with a median (interquartile range [IQR]) age of 391 days [31-3505] and body weight of 9.0 kg [5.0-29.8]. A two-compartment popPK model with first-order elimination and allometric scaling best described cefuroxime disposition. Intravenous cefuroxime clearance was estimated at 5.29 L/h/70 kg. Postnatal age and creatinine clearance (mL/min/1.73 m

conclusionsThese findings indicate that underexposure due to augmented renal function is possible when applying the current cefuroxime dosing regimens. Future research should focus on individualized dosing strategies to optimize cefuroxime exposure and efficacy in pediatric populations.

Indexed as

Anti-Bacterial AgentsCefuroximeAdministration, IntravenousChildChild, PreschoolCohort StudiesCritical IllnessFemaleHumansInfantInfant, NewbornInfusions, IntravenousMaleMicrobial Sensitivity TestsModels, BiologicalAnti-Bacterial AgentsCefuroxime

Identifiers

PMID41182478
PMCPMC12783212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.